Answers are grounded in this paper and cite their sources.
Reported here is a safe, scalable process via a Reformatsky-type reaction of iminium salt ( 4 ) followed by Red-Al reduction giving tert -butyl-4-(2-hydroxyethyl)-4-(pyrrolidin-1-yl)-piperidine-1-carboxylate ( 6 ), an intermediate of novel antiarteriosclerotics ( 1 ). The key points of this safe process are the use of trifluoroacetic acid (TFA) for the iminium salt formation, vigorous stirring for the Reformatsky reaction, and slow addition of methyl bromoacetate. Pilot manufacturing on the 500 L scale was achieved.
No takes yet. Share an insight, caveat, or question.
Osato et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: